ישראל -
עברית -
Ministry of Health
yukon, yukon choice, yukon choice 4, yukon cc
סרפנטיין בע"מ - רופא
ישראל -
עברית -
Ministry of Health
אינטגרילין 0.75 מגמל
merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - תמיסה לאינפוזיה - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.
ישראל -
עברית -
Ministry of Health
אינטגרילין 2 מגמל
merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - תמיסה להזרקה - eptifibatide 2 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.
ישראל -
עברית -
Ministry of Health
אפטיפיבאטיד טבע ® 2 מ"ג/מ"ל
teva pharmaceutical indust.ltd - eptifibatide 2 mg/ml - solution for injection - eptifibatide - eptifibatide teva is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty directional atheretomy transluminal extraction catheter atherectomy rotational ablation angioplasty or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death myorardial infarction need for urgent intervention). eptifibatide is intended for use with aspirin and heparin.
ישראל -
עברית -
Ministry of Health
אטוריקוקסיב – תרימה 120 מג
trima israel pharmaceutical products maabarot ltd - etoricoxib - טבליות מצופות פילם - etoricoxib 120 mg - etoricoxib
ישראל -
עברית -
Ministry of Health
אטוריקוקסיב – תרימה 30 מג
trima israel pharmaceutical products maabarot ltd - etoricoxib - טבליות מצופות פילם - etoricoxib 30 mg - etoricoxib
ישראל -
עברית -
Ministry of Health
אטוריקוקסיב – תרימה 60 מג
trima israel pharmaceutical products maabarot ltd - etoricoxib - טבליות מצופות פילם - etoricoxib 60 mg - etoricoxib
ישראל -
עברית -
Ministry of Health
אטוריקוקסיב – תרימה 90 מג
trima israel pharmaceutical products maabarot ltd - etoricoxib - טבליות מצופות פילם - etoricoxib 90 mg - etoricoxib
ישראל -
עברית -
Ministry of Health
רמיקד
j-c health care ltd - infliximab 100 mg/vial - powder for concentrate for infusion - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther